RELATIONSHIP BETWEEN ANTIPHOSPHOLIPID SYNDROME CLINICAL MANIFESTATIONS AND MULTIPLE POSITIVE ANTIPOSPHOLIPID ANTIBODIES
(Abstract release date: 05/21/15)
EHA Library. Siguenza R. 06/12/15; 102976; PB2057
Disclosure(s): Hospital San Pedro de Alcantara
Dr. Raul Siguenza
Contributions
Contributions
Abstract
Abstract: PB2057
Type: Publication Only
Background
The Antiphospholipid syndrome (APS) is characterized by the development of thrombosis and/or pregnancy complications in addition to the persistent presence of antiphospholipid antibodies (APLS): Lupus Anticoagulant, Anticardiolipin antibodies, Anti-beta 2 GP1 antibodies. At this moment, is not well known that risk factors could be associated to any clinical manifestations of APS.
Aims
We investigated if there are relationship between the different clinical manifestations of APS and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or multiple positive APLS.
Methods
Retrospective we investigated the relationship between clinical manifestations and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or the existence of multiple positive APLS in 65 patients consecutive diagnosed of APS in our hospital from 1 February 2000 to 31 January of 2015. The patients ages were between 21 to 88, gender 53.8% male and 46.2% females. 43 patients present cardiovascular risk factors (26 smokers 24 hypertension, 22 dyslipidemia, 3 Diabetes Mellitus), 21 patients with thrombophilia ( 8 hyperhomocysteinemie, 2 antithrombine deficiency, 3 protein S deficiency, 1 protein C deficiency, 4 FV Leiden mutations and 3 prothrombin G20210A mutation), 17 patients with triple APLS (TP) and 48 with one/double APLS (ODP).
Results
We found statistically significant difference between the presence of TP and the development of arterial thrombosis (OR 0.16 y IC 95% 0.03 – 0.76
Summary
Our data show an association between TP and development of arterial thrombosis in APS patients. We did not found association between one or multiple positivity on APLS and the other clinical manifestations of APS, and the presence or not of cardiovascular risk factor or thrombophilia with clinical manifestations of APS.
Session topic: Publication Only
Type: Publication Only
Background
The Antiphospholipid syndrome (APS) is characterized by the development of thrombosis and/or pregnancy complications in addition to the persistent presence of antiphospholipid antibodies (APLS): Lupus Anticoagulant, Anticardiolipin antibodies, Anti-beta 2 GP1 antibodies. At this moment, is not well known that risk factors could be associated to any clinical manifestations of APS.
Aims
We investigated if there are relationship between the different clinical manifestations of APS and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or multiple positive APLS.
Methods
Retrospective we investigated the relationship between clinical manifestations and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or the existence of multiple positive APLS in 65 patients consecutive diagnosed of APS in our hospital from 1 February 2000 to 31 January of 2015. The patients ages were between 21 to 88, gender 53.8% male and 46.2% females. 43 patients present cardiovascular risk factors (26 smokers 24 hypertension, 22 dyslipidemia, 3 Diabetes Mellitus), 21 patients with thrombophilia ( 8 hyperhomocysteinemie, 2 antithrombine deficiency, 3 protein S deficiency, 1 protein C deficiency, 4 FV Leiden mutations and 3 prothrombin G20210A mutation), 17 patients with triple APLS (TP) and 48 with one/double APLS (ODP).
37 patients presented venous thrombosis (22 deep vein thrombosis, 6 pulmonay embolism, 9 both), 15 patients with arterial thrombosis manifestations (2 arterial thrombosis, 3 myocardial infarction and arterial thrombosis, 10 cerebrovascular accident), 4 with pregnancy complications, and 9 with combined complications (arterial/venous thrombosis/pregnancy complications).
The statistical analysis was performed with Chi2 test realized by JMP 9, being statistically significant p<0.05.
Results
We found statistically significant difference between the presence of TP and the development of arterial thrombosis (OR 0.16 y IC 95% 0.03 – 0.76
p=0.01).
Summary
Our data show an association between TP and development of arterial thrombosis in APS patients. We did not found association between one or multiple positivity on APLS and the other clinical manifestations of APS, and the presence or not of cardiovascular risk factor or thrombophilia with clinical manifestations of APS.
Session topic: Publication Only
Abstract: PB2057
Type: Publication Only
Background
The Antiphospholipid syndrome (APS) is characterized by the development of thrombosis and/or pregnancy complications in addition to the persistent presence of antiphospholipid antibodies (APLS): Lupus Anticoagulant, Anticardiolipin antibodies, Anti-beta 2 GP1 antibodies. At this moment, is not well known that risk factors could be associated to any clinical manifestations of APS.
Aims
We investigated if there are relationship between the different clinical manifestations of APS and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or multiple positive APLS.
Methods
Retrospective we investigated the relationship between clinical manifestations and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or the existence of multiple positive APLS in 65 patients consecutive diagnosed of APS in our hospital from 1 February 2000 to 31 January of 2015. The patients ages were between 21 to 88, gender 53.8% male and 46.2% females. 43 patients present cardiovascular risk factors (26 smokers 24 hypertension, 22 dyslipidemia, 3 Diabetes Mellitus), 21 patients with thrombophilia ( 8 hyperhomocysteinemie, 2 antithrombine deficiency, 3 protein S deficiency, 1 protein C deficiency, 4 FV Leiden mutations and 3 prothrombin G20210A mutation), 17 patients with triple APLS (TP) and 48 with one/double APLS (ODP).
Results
We found statistically significant difference between the presence of TP and the development of arterial thrombosis (OR 0.16 y IC 95% 0.03 – 0.76
Summary
Our data show an association between TP and development of arterial thrombosis in APS patients. We did not found association between one or multiple positivity on APLS and the other clinical manifestations of APS, and the presence or not of cardiovascular risk factor or thrombophilia with clinical manifestations of APS.
Session topic: Publication Only
Type: Publication Only
Background
The Antiphospholipid syndrome (APS) is characterized by the development of thrombosis and/or pregnancy complications in addition to the persistent presence of antiphospholipid antibodies (APLS): Lupus Anticoagulant, Anticardiolipin antibodies, Anti-beta 2 GP1 antibodies. At this moment, is not well known that risk factors could be associated to any clinical manifestations of APS.
Aims
We investigated if there are relationship between the different clinical manifestations of APS and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or multiple positive APLS.
Methods
Retrospective we investigated the relationship between clinical manifestations and the presence of cardiovascular risk factors, hereditary and acquired thrombophilia or the existence of multiple positive APLS in 65 patients consecutive diagnosed of APS in our hospital from 1 February 2000 to 31 January of 2015. The patients ages were between 21 to 88, gender 53.8% male and 46.2% females. 43 patients present cardiovascular risk factors (26 smokers 24 hypertension, 22 dyslipidemia, 3 Diabetes Mellitus), 21 patients with thrombophilia ( 8 hyperhomocysteinemie, 2 antithrombine deficiency, 3 protein S deficiency, 1 protein C deficiency, 4 FV Leiden mutations and 3 prothrombin G20210A mutation), 17 patients with triple APLS (TP) and 48 with one/double APLS (ODP).
37 patients presented venous thrombosis (22 deep vein thrombosis, 6 pulmonay embolism, 9 both), 15 patients with arterial thrombosis manifestations (2 arterial thrombosis, 3 myocardial infarction and arterial thrombosis, 10 cerebrovascular accident), 4 with pregnancy complications, and 9 with combined complications (arterial/venous thrombosis/pregnancy complications).
The statistical analysis was performed with Chi2 test realized by JMP 9, being statistically significant p<0.05.
Results
We found statistically significant difference between the presence of TP and the development of arterial thrombosis (OR 0.16 y IC 95% 0.03 – 0.76
p=0.01).
Summary
Our data show an association between TP and development of arterial thrombosis in APS patients. We did not found association between one or multiple positivity on APLS and the other clinical manifestations of APS, and the presence or not of cardiovascular risk factor or thrombophilia with clinical manifestations of APS.
Session topic: Publication Only
{{ help_message }}
{{filter}}